Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)

PR Newswire June 29, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 12, 2022 in Axsome Lawsuit - AXSM

Newsfile June 29, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)

PR Newswire June 29, 2022

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Newsfile June 28, 2022

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

GlobeNewswire June 28, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

PR Newswire June 28, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Limited Shareholders

Newsfile June 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

PR Newswire June 27, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022

PR Newswire June 27, 2022

AXSM INVESTOR NEWS: NATIONALLY RANKED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

Newsfile June 27, 2022

Axsome Class Action: Levi & Korsinsky Reminds Axsome Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2022 - AXSM

Newsfile June 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

Newsfile June 25, 2022

ROSEN, A TOP RANKED FIRM, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

Newsfile June 24, 2022

AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)

PR Newswire June 24, 2022

AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022

PR Newswire June 24, 2022

AXSM LOSS ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

PR Newswire June 23, 2022

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 23, 2022

AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire June 22, 2022

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

GlobeNewswire June 22, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)

PR Newswire June 22, 2022